First-Line Pembrolizumab Plus Chemotherapy for Advanced Biliary Tract Cancer: China Subgroup Analysis of the Randomized Phase 3 KEYNOTE-966 Study.
| Publicado en: | Advances in Therapy Vol. 43; no. 9; pp. 3871 - 3886 |
|---|---|
| Autores principales: | , , , , , , , , , , , , , , , , , , , |
| Formato: | Journal Article |
| Publicado: |
Springer Nature
Sep2026
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=196381600&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 196381600 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 0741238X 1XDX jtl: Advances in Therapy issn: 0741238X maglogo: N pubinfo: dt: Sep2026 vid: 43 iid: 9 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 196381600 193921952 10.1007/s12325-026-03578-4 196381600 ppf: 3871 ppct: 15 formats: tig: atl: First-Line Pembrolizumab Plus Chemotherapy for Advanced Biliary Tract Cancer: China Subgroup Analysis of the Randomized Phase 3 KEYNOTE-966 Study. aug: au: Ren, Zhenggang Liang, Tingbo Gu, Shanzhi Gou, Hongfeng Peng, Chuang Pan, Yueyin Song, Tianqiang Su, Haichuan Cao, Ke Liang, Houjie Ying, Jieer Geng, Zhimin Yu, Wenchang Zhao, Haitao Bai, Yuxian Hao, Chunyi Mao, Yimin Li, Wei Wang, Lu Li, Dongliang affil: https://ror.org/013q1eq08 Department of Hepatic Oncology, Liver Cancer Institute, Zhongshan Hospital, Fudan University, National Clinical Research Center for Interventional Medicine, Shanghai, China sug: pubtype: Academic Journal doctype: Journal Article ougenre: Article ab: language: English refInfo: holdings: @attributes: islocal: N |
|---|